Summary
We are delighted to share that the ICM - Institut du Cancer de Montpellier was authorized by the French Data Protection Authority (CNIL) to conduct APAD-ECO study.
The CNIL granted authorization to conduct a medico-economic study on the effects of physical activity in women treated for breast cancer on April, 19th. This groundbreaking study involves combining data from two clinical trials with that of the Caisse nationale de l’Assurance Maladie, covering the period from 2009 to 2022.
The study aims to assess the long-term impacts of physical activity in patients who have undergone treatment for breast cancer.
We are proud to have contributed to this project by providing the ICM - Institut du Cancer de Montpellier with a compliant Data Protection Impact Assessment (DPIA), a crucial step in obtaining CNIL approval.
FAQs
Our frequently questions
Find out how iliomad can help your company.
Only visible in production
MR-001 CNIL: what clinical trial sponsors must know about French health data compliance
Understand MR-001 CNIL obligations for clinical trial sponsors in France, from Article 32 security requirements to breach notification and cross-border data transfers.
ICF Boilerplate and Open-Access Database Disclosures: What Clinical Trial Sponsors Must Know
Learn how US site ICF boilerplate on commercial products and open-access genetic databases affects sponsor data governance, Common Rule compliance and GDPR obligations.
iliomad Weekly Digest: DPO Conflicts, Bulk Data Rules, Healthcare Cyber Incidents and AI Transparency
This week: CNIL on DPO conflicts of interest, DOJ bulk data rule for life sciences, wave of healthcare ransomware attacks, Uber's €825m GDPR fine and AI disclosure demands.
